Dew, if TEVA is using an injector for delivery of low volume Copaxone would this still be filed as a supplemental NDA? What time-line would the FDA follow for this type of review? One of the analysts asked this question on the call and management didn't deny an injector was being utilized in the study.
Market Data 
Markets 
AI
